Clinical Trial

Autologous SVF Therapy for Type 2 Diabetes

Study acronym: LASER-DM2 Tria
Recruiting
View on ClinicalTrials.gov →
Summary
This prospective clinical study aims to evaluate the safety and efficacy of autologous adipose-derived stromal vascular fraction (SVF), enriched with mesenchymal stem cells (ADSCs), for the treatment of Type 2 Diabetes Mellitus (T2DM). Adipose tissue will be harvested using a 1210-nm diode laser-assisted selective photochemical stimulation technique (One-STEP™ method), followed by centrifugation without enzymatic digestion. The isolated SVF will be injected endoluminally into the duodenal submucosa during the same surgical procedure. Five adult patients with T2DM will be followed for six months to assess metabolic control, pancreatic function, and quality of life outcomes.
Trial Details
NCT Number NCT07487467
Lead Sponsor Kaiser Clinic and Hospital
Conditions Diabetes Mellitus, Type 2
Enrollment 10 participants
Start Date 2025-01-20
Primary Completion 2026-03-16 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-23